Surrozen (SRZN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
1 Apr, 2026Executive summary
The annual meeting will be held virtually on May 13, 2026, with voting available online, by phone, or by mail.
Stockholders will vote on director elections, auditor ratification, executive compensation, and the frequency of say-on-pay votes.
Holders of record as of March 18, 2026, are entitled to vote; a quorum requires one-third of outstanding shares.
Voting matters and shareholder proposals
Election of two Class II directors (Mace Rothenberg, M.D. and David J. Woodhouse, Ph.D.) for terms expiring in 2029.
Ratification of Ernst & Young LLP as independent auditor for 2026.
Advisory vote on executive compensation and on the preferred frequency of such votes (Board recommends annual frequency).
Stockholders may submit proposals for the 2027 meeting by specified deadlines and procedures.
Board of directors and corporate governance
Board consists of eight directors divided into three classes with staggered terms.
Majority of directors are independent per Nasdaq standards; CEO and Chair roles are separated.
Three standing committees: audit, compensation, and nominating/corporate governance, each with defined responsibilities and independent members.
Board and committees met regularly in 2025; all directors except one attended at least 75% of meetings.
Board emphasizes diversity, integrity, and relevant experience in director nominations.
Latest events from Surrozen
- Lead dual-mechanism therapy SZN-8141 enters trials, targeting major unmet needs in retinal disease.SRZN
Morgan Stanley 24th Annual Global Healthcare Conference - DUET study launches this year for a dual VEGF/Wnt therapy in DME, with initial data in 2027.SRZN
12th Annual Cantor Fitzgerald Global Healthcare Conference - Multifunctional antibodies targeting Wnt, VEGF, and IL-6 aim to transform retinal disease treatment.SRZN
Corporate presentation - Q2 2026 net income was $50.2M, with SZN-8141 IND and DUET trial milestones progressing.SRZN
Q2 2026 - Dual-targeting Wnt and VEGF therapies show synergistic efficacy in retinal disease models.SRZN
H.C. Wainwright 6th Annual Ophthalmology Virtual Conference - SZN-8141 targets retinal diseases by combining Wnt agonism and VEGF inhibition for enhanced efficacy.SRZN
H.C. Wainwright 4th Annual BioConnect Investor Conference - All agenda items passed, including director elections and annual advisory votes on compensation.SRZN
AGM 2026 - Multi-functional antibodies targeting Wnt, VEGF, and IL-6 address major unmet needs in retinal disease.SRZN
Corporate presentation - Net loss widened to $127.5M as cash reached $106.9M; IND for SZN-8141 on track for H2 2026.SRZN
Q1 2026